An interesting report shows that a combinatorial inhibition of EZH2 and DNA methylation re-sensitizes immunomodulatory drug (IMiD)-resistant MM cells to lenalidomide or pomalidomide treatment [116]. The gene discussed is EZH2; the disease is Miyoshi myopathy.